Your browser doesn't support javascript.
loading
Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
Lee, Dae Ho; Kim, Hye Ryun; Keam, Bhumsuk; Kato, Ken; Kuboki, Yasutoshi; Gao, Haiyan; Yovine, Alejandro; Robbins, Scott H; Ahn, Myung-Ju.
Affiliation
  • Lee DH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Kato K; Department of Head and Neck, Esophageal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Kuboki Y; Gastrointestinal Oncology Division, National Cancer Center Hospital, East Kashiwa, Japan.
  • Gao H; AstraZeneca, Cambridge, UK.
  • Yovine A; AstraZeneca, Cambridge, UK.
  • Robbins SH; AstraZeneca, Gaithersburg, Maryland, USA.
  • Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Cancer Med ; 12(15): 16066-16075, 2023 08.
Article in En | MEDLINE | ID: mdl-37489066

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Esophageal Squamous Cell Carcinoma Type of study: Clinical_trials / Etiology_studies Limits: Adult / Aged / Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Esophageal Squamous Cell Carcinoma Type of study: Clinical_trials / Etiology_studies Limits: Adult / Aged / Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication: